Susanna Juteau

Immunohistochemical Predictors in Head and Neck Mucosal Melanoma

Sara C. Degerholm, Tuula Anneli Salo, Susanna Juteau, Matti Mauramo

BACKGROUND: Mucosal melanoma is a rare disease with a poor prognosis, and its clinical signs and symptoms are nonspecific. This study aims to identify histopathological features and immunohistochemical markers of head and neck mucosal melanoma that characterize the tumor immunophenotype and are …

fi (code pays fourni par la source)

Immune-cytokine signature predicts survival in patients with advanced melanoma treated with oncolytic adenovirus TILT-123 and chemotherapy and IL-2-free adoptive TIL therapy

Lyna Haybout, Tatiana Viktorovna Kudling, James H.A. Clubb, Tine Juul Monberg et autres

BACKGROUND: Metastatic melanoma resistant to immune checkpoint inhibitors remains difficult to treat, and while adoptive tumor-infiltrating lymphocyte (TIL) therapy has shown durable responses, its reliance on lymphodepleting chemotherapy and high-dose interleukin (IL)-2 causes toxicity that may limit patient eligibility. The dual-cytokine-armed oncolytic …

fi, dk, fr (code pays fourni par la source)

Extended monitoring and biomarker analysis in metastatic melanoma patients treated with TIL therapy and conditioning-replacing igrelimogene litadenorepvec virotherapy: Pre-infusion immune cell and cytokine profiles associated with survival.

Víctor Cervera-Carrascón, Tatiana Viktorovna Kudling, James Clubb, Lyna Haybout et autres

2538 Background: Adoptive transfer of tumor-infiltrating lymphocytes (TILs) can be effective in metastatic melanoma, but its routine use is limited by the need for lymphodepleting chemotherapy and systemic high-dose IL-2. To reduce toxicity while preserving antitumor activity, a strategy pairing TIL therapy …

fi, dk, fr (code pays fourni par la source)

514 Biomarker insights and long-term outcomes of TILT-123 oncolytic adenovirus combined with tumor-infiltrating lymphocytes in refractory metastatic melanoma: results from the TUNINTIL phase 1 trial

Tatiana Viktorovna Kudling, Lyna Haybout, James H.A. Clubb, Tine Juul Monberg et autres

Background Tumor-infiltrating lymphocyte (TIL) therapy was recently approved by the FDA for metastatic melanoma (MM), but its widespread implementation remains limited by significant toxicities associated with lymphodepleting chemotherapy and high-dose IL-2 regimens. Phase 1 trial TUNINTIL ( NCT04217473) evaluated a novel design …

fi, dk, fr (code pays fourni par la source)

Association of Pretreatment Tumour Microenvironment and Treatment Outcome in Patients With Locally Advanced Melanoma Treated With Isolated Limb Perfusion

Sanni K. A. Tulokas, Susanna Juteau, Siru Mäkelä, Katja E. Välimäki et autres

As effective melanoma treatments have become available, utilizing isolated limb perfusion (ILP) to treat unresectable melanoma limited to the limb has decreased. However, some patients still receive long-term benefits from ILP. We aimed to identify features of the pretreatment tumor microenvironment (TME) …

fi (code pays fourni par la source)

Neutralizing antibodies and lymphocyte count as biomarkers in patients receiving oncolytic adenovirus TILT-123 and adoptive cell transfer of tumor-infiltrating lymphocytes for metastatic melanoma refractory to immune checkpoint inhibitors.

Lyna Haybout, James H.A. Clubb, Tine Juul Monberg, Santeri Artturi Pakola et autres

9518 Background: Metastatic melanoma refractory to immune checkpoint inhibitors (ICI) remains a significant challenge. Adoptive Cell Transfer of Tumor-Infiltrating Lymphocytes (ACT-TILs) shows promise but can cause adverse events. Oncolytic adenovirus TILT-123 (igrelimogene litadenorepvec) coding for TNF and IL2 combined with ACT-TILs, offers …

fi, dk, fr (code pays fourni par la source)

Figure 2 from Safety, Efficacy, and Biological Data of T-Cell–Enabling Oncolytic Adenovirus TILT-123 in Advanced Solid Cancers from the TUNIMO Monotherapy Phase I Trial

Santeri Artturi Pakola, Katriina Johanna Peltola, James H.A. Clubb, Elise Jirovec et autres

A, Response evaluation in all injected lesions, evaluated by CT. B, Response evaluation in all injected lesions, evaluated by PET. C, Response evaluation in allimaged non-injected lesions, evaluated by CT. D, Response evaluation in all imaged non-injected lesions, evaluated by PET. Best …

Supplementary Data 1 from Safety, Efficacy, and Biological Data of T-Cell–Enabling Oncolytic Adenovirus TILT-123 in Advanced Solid Cancers from the TUNIMO Monotherapy Phase I Trial

Santeri Artturi Pakola, Katriina Johanna Peltola, James H.A. Clubb, Elise Jirovec et autres

Supplementary Table S1-S5, Supplementary Figure S1-S6

Table 1 from Safety, Efficacy, and Biological Data of T-Cell–Enabling Oncolytic Adenovirus TILT-123 in Advanced Solid Cancers from the TUNIMO Monotherapy Phase I Trial

Santeri Artturi Pakola, Katriina Johanna Peltola, James H.A. Clubb, Elise Jirovec et autres

Patient demographics.

Supplementary Data 1 from Safety, Efficacy, and Biological Data of T-Cell–Enabling Oncolytic Adenovirus TILT-123 in Advanced Solid Cancers from the TUNIMO Monotherapy Phase I Trial

Santeri Artturi Pakola, Katriina Johanna Peltola, James H.A. Clubb, Elise Jirovec et autres

Supplementary Table S1-S5, Supplementary Figure S1-S6

Figure 1 from Safety, Efficacy, and Biological Data of T-Cell–Enabling Oncolytic Adenovirus TILT-123 in Advanced Solid Cancers from the TUNIMO Monotherapy Phase I Trial

Santeri Artturi Pakola, Katriina Johanna Peltola, James H.A. Clubb, Elise Jirovec et autres

A, Trial outline. B, Lymphocyte changes after TILT-123, all cohorts pooled. C, Leukocyte changes after TILT-123, all cohorts pooled. D, Neutrophil changes after TILT-123, all cohorts pooled. E, Virus detection in blood by qPCR, before treatment, 1 hour post-treatment and 16 hours …

Table 2 from Safety, Efficacy, and Biological Data of T-Cell–Enabling Oncolytic Adenovirus TILT-123 in Advanced Solid Cancers from the TUNIMO Monotherapy Phase I Trial

Santeri Artturi Pakola, Katriina Johanna Peltola, James H.A. Clubb, Elise Jirovec et autres

Adverse events related to TILT-123 therapy as judged and reported by the investigator, stratified by grade, cohort, and unique patients with reported adverse event.a